204 related articles for article (PubMed ID: 36593474)
21. Patient reminder and recall interventions to improve immunization rates.
Jacobson Vann JC; Jacobson RM; Coyne-Beasley T; Asafu-Adjei JK; Szilagyi PG
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003941. PubMed ID: 29342498
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.
Ward KF; Trent M; Hull BP; Quinn HE; Dey A; Menzies RI
BMC Health Serv Res; 2015 Mar; 15():109. PubMed ID: 25889782
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Community Health; 2020 Feb; 45(1):111-120. PubMed ID: 31401746
[TBL] [Abstract][Full Text] [Related]
26. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up.
Vila-Córcoles A; Ochoa-Gondar O; Ester F; Sarrá N; Ansa X; Saún N;
BMC Public Health; 2006 Sep; 6():231. PubMed ID: 16981982
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
28. Use of Information and Communication Technology Strategies to Increase Vaccination Coverage in Older Adults: A Systematic Review.
Buja A; Grotto G; Taha M; Cocchio S; Baldo V
Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515089
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review.
Shao Y; Stoecker C
Expert Rev Vaccines; 2020 Dec; 19(12):1141-1151. PubMed ID: 33428494
[TBL] [Abstract][Full Text] [Related]
30. Pneumococcal vaccination in older adults: An initial analysis of social determinants of health and vaccine uptake.
Gatwood J; Shuvo S; Hohmeier KC; Hagemann T; Chiu CY; Tong R; Ramachandran S
Vaccine; 2020 Jul; 38(35):5607-5617. PubMed ID: 32654903
[TBL] [Abstract][Full Text] [Related]
31. Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.
Trent MJ; Salmon DA; MacIntyre CR
Vaccine; 2022 Feb; 40(8):1152-1161. PubMed ID: 35078659
[TBL] [Abstract][Full Text] [Related]
32. A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis.
Baker DW; Brown T; Lee JY; Ozanich A; Liss DT; Sandler DS; Ruderman EM
J Rheumatol; 2016 Jun; 43(6):1030-7. PubMed ID: 27084914
[TBL] [Abstract][Full Text] [Related]
33. Vaccines for older adults.
Lam S; Jodlowski TZ
Consult Pharm; 2009 May; 24(5):380-91. PubMed ID: 19555147
[TBL] [Abstract][Full Text] [Related]
34. The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia.
Chen C; Wood JG; Beutels P; Menzies R; MacIntyre CR; Dirmesropian S; Reyes JF; McIntyre P; Newall AT
Vaccine; 2018 Feb; 36(10):1265-1271. PubMed ID: 29395534
[TBL] [Abstract][Full Text] [Related]
35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
36. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States.
McLaughlin JM; Swerdlow DL; Khan F; Will O; Curry A; Snow V; Isturiz RE; Jodar L
Hum Vaccin Immunother; 2019; 15(4):841-849. PubMed ID: 30676236
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of email-based reminders to increase vaccine uptake: a systematic review.
Frascella B; Oradini-Alacreu A; Balzarini F; Signorelli C; Lopalco PL; Odone A
Vaccine; 2020 Jan; 38(3):433-443. PubMed ID: 31806532
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 Vaccine Hesitancy-A Scoping Review of Literature in High-Income Countries.
Aw J; Seng JJB; Seah SSY; Low LL
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
